Goodrx shares jumps 20% at $ 499 Novo Nordisk Drug Deal
Goodrx (Nasdaq: GDRX) increased almost 20% on Monday after announcing an agreement with Novo Nordisk (NYSE: NVO) to sell its GLP-1 drugs of great success, Ozmpic for diabetes and the growing for weight control, at a fixed cash price of $ 499 per month. The measure is significant not only for patients fighting with affordableness,…